Exelixis wins patent case against MSN; generic launch blocked until Jan 2030

EXELIXIS, INC.

Delaware court rejected MSN's invalidity challenges to three cabozantinib patents (11,091,439, 11,091,440, 11,098,015), all expiring Jan 15, 2030.
Court found MSN's ANDA product infringes those three patents; separate patent 11,298,349 (exp 2032) was not infringed.
Final judgment due Oct 22; FDA cannot approve MSN's generic before Jan 15, 2030 at the earliest.
Ruling protects Exelixis' cabozantinib franchise from generic entry for over five additional years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.